To determine whether altered beta-adrenergic responses contribute to early cardiac dysfunction in mdx (X-linked muscular dystrophy) mice, an animal model for human Duchenne muscular dystrophy.
Introduction
Duchenne muscular dystrophy (DMD) is a highly lethal X-linked recessive (mdx) genetic disease, affecting 1 in 3500 male births worldwide. The disease is caused by mutations in the dystrophin gene which is located on the X-chromosome, resulting in non-functional dystrophin. 1 Dystrophin normally links cytoskeletal proteins to sarcolemmal glycoproteins to form the dystrophin-associated glycoprotein complex. The loss of dystrophin leads to unstable membranes and increased sensitivity to mechanical stress in muscle cells, 2 causing muscle degeneration due to Ca 2+ overload. An early manifestation of DMD is skeletal muscle weakness, 3 which impairs the diaphragm, ultimately leading to respiratory failure in † Y.L. and S.Z. contributed equally to this work.
DMD patients. 1 At the late stage of DMD, cardiac dysfunction is an evident feature and a significant contributing factor for mortality. 4 Now supported by mechanical ventilators, more DMD patients are surviving with cardiac dysfunction and eventually dilated cardiomyopathy. 3 An important function of the heart is to adapt to increased needs for tissue perfusion under normal physiological conditions. This adaptation is achieved by the activation of the sympathoadrenergic system (SAS). The SAS can persistently be activated when the heart is under stress, leading to a reduced beta-adrenergic response. The reduction in cardiac beta-adrenergic reserve in response to increased demand of cardiac output is an early feature of diseased hearts. 5, 6 In the clinic, the treadmill test and dobutamine stress test have widely been used to evaluate cardiac reserve. However, to the best of our knowledge, there is no report on cardiac reserve in DMD patients. Furthermore, since cardiac dysfunction in DMD patients is usually diagnosed at rest and can only be detected at a late stage, the treatment for cardiac dysfunction is usually only initiated at that stage. 7 The mdx mouse is a model of human DMD, carrying a stop codon mutation in exon 23 of the dystrophin gene. In mdx mice, as in human DMD patients, cardiac dysfunction has been monitored only at a late stage of the disease. 8 Few studies have been conducted to determine cardiac reserve in mdx mice, which is the topic of this study. We determined in vivo and ex vivo cardiac beta-adrenergic responses in mdx and control mice at different ages and further explored the cellular and molecular mechanisms for the altered beta-adrenergic response in mdx mice. Our data suggest that loss of cardiomyocytes in the early stages is compensated by a significant enhancement of myocyte contractile function to maintain whole-heart function in mdx mice, which is brought about by increasing basal phosphorylation of Ca 2+ handling
proteins. This remodelling combined with reduced myocyte beta1-adrenergic receptor (b1-AR) density decreased the residual whole-heart beta-adrenergic response in young mdx mice.
Methods

Animals
All mice were handled in compliance with the 'Principles of Laboratory Animal Care' formulated by the National Society for Medical Research and the 'Guide for the Care and Use of Laboratory Animals' published by the National Institutes of Health (NIH publication 85-23, revised 1996). All animal protocols were approved by the Animal Care and Use Committee of Temple University. Mdx (C57BL/10ScSn-Dmdmdx/J mice) and control mice (C57BL/10ScSn) breeding pairs were purchased from the Jackson Laboratory. Animals were studied at the ages of 2, 3, 4, 5, 6, 7, 8, and 12 months for echocardiography (ECHO) analysis and at 2, 4, 8, and 12 months for all other investigations. Tissue harvesting and myocyte isolation were performed after animal euthanasia using 120 mg/kg sodium pentobarbital (ip). Tribromoethanol (250 mg/kg, ip) was used for non-survival surgery to measure intra-left ventricle (LV) haemodynamics. For ECHO, mice were anaesthetized with 2% isoflurane initially, then with 1%. Tail and toe pinch reflexes were checked to ensure adequate anaesthesia.
Cardiac fibrosis and function evaluation
Standard histology and Masson's trichrome staining were used to quantitate myocardial fibrosis. 9 ECHO was performed with a VisualSonics Vevo 770 machine 9 to evaluate cardiac function and cardiac geometry in mdx and control mice. Intra-LV pressure was measured with a 1.4-F Millar catheter (SPR-839, Millar Instruments, Houston, TX, USA) before and after isoproterenol (ISO) as described previously. 10 Eight doses of ISO [10 216 -10 29 g ISO/g body weight (BW)] were applied through the jugular vein cannula. ISO was selected because it has equal affinity for both b1-and b2-ARs and it is not known which type of receptor is altered in mdx animals.
Mouse Langendorff heart perfusion
The Langendorff-perfused heart preparation was established as described previously. 11 Eight doses of ISO (10 212 -10 25 M) were applied through the perfusate to stimulate the heart. -free solutions at 358C as described previously. 1 Charge movement, Q on and Q off , of the L-type calcium channel in mdx and control myocytes were measured as described previously. 10 
Contraction
Western blotting
Standard western blot procedures were performed to detect alterations in the abundance of calcium handling proteins and their phosphorylation, and the b-ARs.
Protein kinase A activity measurement
Protein kinase A (PKA) activity of non-stimulated or ISO-stimulated hearts was measured with an enzyme-linked immunosorbent assay (ELISA)-based PKA activity kit (Assay Design, Ann Arbor, MI, USA) according to the manufacturer's instructions. Mouse ventricle samples were homogenized in lysis buffer supplemented with 0.4 mM IBMX (3-isobutyl-methylxanthine, a nonspecific inhibitor of phosphodiesterases). PKA activity in the homogenate was then determined.
Statistics
Data are reported as mean + standard error of the mean. Unpaired t-test, two-way analysis of variance (ANOVA), or two-way ANOVAs for repeated measures were used to detect statistical significance with GraphPad Prism. 5 All cell measurements from the same heart were averaged as one averaged data point. At least three cells from each heart were studied. For three-factor (genotype, age, and drug) statistical analysis, a mixed procedure was performed for covariance analysis and overall significance evaluation, followed by effect size testing to determine the effect of each factor on the analysed parameter. Post hoc test with Bonferroni adjustment was done to determine pairwise differences.
In all tests, P-values of ≤0.05 were considered significant. Detailed 'Materials and methods' are described in Supplementary materials online.
Reduced cardiac beta-adrenergic response in mdx mice 3. Results 3.1 Myocardial fibrosis in mdx mice begins at the age of 2 months, but baseline cardiac dysfunction and morphological changes are only detected from 8 months onwards Mdx mice are characterized by the loss of cardiomyocytes and replacement fibrosis. While there was a little change in collagen content in control mice during the 1-year study, fibrosis in mdx mice began to appear at the age of 2 months and gradually reached its maximum at the age of 8 months ( Figure 1A and B) .
Chronic loss of cardiomyocytes and fibrosis may significantly impact cardiac function. Therefore, cardiac function of mdx mice was evaluated over time. At baseline, when the heart rate was controlled in the range of 400 -450 bpm ( Figure 1C and see Supplementary material online, Figure S1A ), cardiac contractile function indicated by fractional shortening (FS; see Supplementary material online, Figure S1B ), systolic pressure ( Figure 1D ), developed pressure ( Figure 1F) , and maximal +dp/dt ( Figure 1G ) was significantly depressed only in mdx mice aged ≥8 months compared with age-matched control mice. In contrast, the diastolic pressure ( Figure 1E ) was elevated, and relaxation (minimum 2dp/dt, Figure 1H ) was impaired in mdx mice at ≥8 months but not in control mice. It seems that significant basal cardiac contraction depression and relaxation impairment appeared at the age when there was maximum myocardial fibrosis, most probably because at this time point fibrosis impairs cardiac relaxation, with the surviving myocytes not able to compensate fully for the lost myocytes.
Morphologically, mdx mice had a thicker diastolic LV posterior wall (see Supplementary material online, Figure S1C ) and interventricular septum (see Supplementary material online, Figure S1D ) from 8 months onwards, causing slight decreases in diastolic LV internal diameter (see Supplementary material online, Figure S1E ). Finally, the LV mass was significantly increased in 10-and 12-month-old mdx mice Figure 1 Cardiac fibrosis starts at a young age (2 months) in mdx mice, but baseline cardiac dysfunction is only detected from 8 months onwards. , end-diastolic pressure (EDP; E), developed pressure (F ), maximum +dp/dt (G), and minimum 2dp/dt (H ) determined by intra-LV haemodynamic measurements at the same heart rates (400 -450 bpm, C) in control and mdx mice at different ages (2, 4, 8, and 12 months). *P , 0.05, **P , 0.01, ***P , 0.001 control vs. mdx mice at the same age, respectively; @ P , 0.05; 4-vs. 2-month-old mdx mice; compared with age-matched control and 2-month-old mdx mice (see Supplementary material online, Figure S1F ).
Young mdx hearts have reduced beta-adrenergic responses in vivo
It is well known that hearts at the compensatory stage during heart disease progression have a normal basal cardiac function but a reduced beta-adrenergic response. 12 Therefore, the beta-adrenergic responses of 4-month-old mdx hearts with normal basal cardiac function and 8-month-old mdx hearts with depressed basal cardiac function were compared with those of age-matched control hearts. A high dose of ISO (2 mg/kg BW) was injected ip to test its effect on cardiac function as monitored by intra-LV pressure recording ( Figure 2 ). Steady-state effects of ISO on cardiac performance were compared. Agreeing with the ECHO results, at baseline, 8-month-old mdx hearts had a decreased +dp/dt, increased end-diastolic pressure, and decreased relaxation rate (2dp/dt) compared with 8-month-old control and 4-month-old mdx hearts ( Figure 2E , G, and H ). ISO increased the heart rates in both groups to the same level ( Figure 2A -C) at the ages of 4 and 8 months.
However, ISO only increased systolic pressure, developed pressure, maximum +dp/dt, and minimum 2dp/dt in control mice ( Figure 2D and F-H), as previously reported. 10 ISO instead decreased these parameters in 4-and 8-month-old mdx hearts. ISO also increased diastolic pressure in 8-month-old mdx hearts, but not in other groups ( Figure 2E ).
Since only a single high dose of ISO was used in Figure 2 , subsaturating concentrations (10 216 -10 29 g ISO/g BW, intrajugular vein injection) of ISO were used to better differentiate beta-adrenergic responses between mdx and control hearts at different ages (2, 4, 8, and 12 months) ( Figure 3 and see Supplementary material online, Figure S2 ). In mdx mice of all ages, the heart rate had responses to different doses of ISO comparable with that in age-matched control mice. ISO at these concentrations had comparable effects on maximum +dp/dt, minimum 2dp/dt, and developed pressure in 2-month-old mdx and control mice ( Figure 3A-D) . In 4-month-old animals, ISO did not enhance cardiac function in mdx hearts to the same extent as in control hearts ( Figure 3E-H) . At the ages of 8 and 12 months, there was decreased baseline maximum +dp/dt, minimum 2dp/dt, and developed pressure in mdx mice, and these parameters could not be increased to the same extent in mdx hearts as in control hearts ( Figure 3I -P). Basal and maximum response to ISO of the Figure 2 Mdx hearts have reduced beta-adrenergic responses at 4 and 8 months. (A and B) Examples of intra-LV pressure recordings, derived dp/dt, and heart rates with a saturating dose of ISO (2 mg/kg BW) in 4-month-old control mice (A) and mdx mice (B). (C-H) Systolic pressure (D), diastolic pressure (E), developed pressure (F), maximum +dp/dt (G), and minimum 2dp/dt (H ) determined by intra-LV haemodynamic measurements at the same heart rates (400 -450 bpm, C) in control and mdx mice at the ages of 4 and 8 months. Mixed procedure and post hoc test with Bonferroni adjustment were performed for statistical significance between groups with SAS 9.
Reduced cardiac beta-adrenergic response in mdx mice heart rate, developed pressure, maximum +dp/dt, and minimum 2 dp/dt in control and mdx mice are depicted in Supplementary material online, Figure S2 . Taken together, these results suggest that ≥4-month-old mdx ventricles have blunted beta-adrenergic responses.
Reduced beta-adrenergic responses are the characteristic of young mdx hearts
Since in vivo studies may be complicated by feedback regulatory mechanisms such as concomitant activation of the parasympathetic system, we further tested if the reduced beta-adrenergic response of 4-month-old mdx hearts was an intrinsic property of these hearts. We examined the responses of ex vivo hearts perfused on a Langendorff apparatus to different concentrations of ISO (10 212 -10 25 M). Hearts from both groups of mice started to respond to ISO at 10 211 M and reached a maximal response at a concentration of 10 27 M. The EC 50 of ISO on the heart rate, developed pressure, maximum +dp/dt, and minimum 2dp/dt ( 5 × 10 210 M) of perfused control and mdx hearts were not significantly altered, but tended to be greater in mdx hearts. ISO at doses .10 210 M increased developed pressure, maximum +dp/dt, and minimum 2dp/dt more in control hearts than in mdx hearts ( Figure 4 ). These data suggest that the reduced cardiac beta-adrenergic response in mdx hearts is an intrinsic property of the heart. Figure 5A and B) . However, diastolic sarcomere length was not different between 4-month-old mdx and control myocytes when stimulated at 0.5 Hz (see Supplementary material online, Figure S3 ). These data suggest that young myocytes in mdx hearts develop hypercontraction to compensate for the loss of myocytes, but this compensation leads to reduced potential for mdx myocytes to respond to maximal beta-adrenergic stimulation. In addition, in older mdx myocytes, there were reduced beta-adrenergic responses compared with age-matched control myocytes. content at baseline and after ISO in control myocytes, but had a complex effect on the SR Ca 2+ content in mdx myocytes. At baseline, the SR Ca 2+ content was not changed in 2-month-old mdx myocytes, but was increased in 4-month-old mdx myocytes compared with 2-month-old mdx and age-matched control myocytes. Then, it was decreased to normal in 8-month-old mdx myocytes and to less than in 2-month-old mdx myocytes and age-matched control myocytes in 12-month-old mdx myocytes ( Figure 5C ). After ISO stimulation, SR Ca 2+ content was significantly increased to the same in 2-and 4-month-old control and mdx myocytes, but reduced in 8-and 12-month-old mdx myocytes. We further determined the I Ca and its response to ISO in control and mdx myocytes at different ages. Age did not affect baseline I Ca in control myocytes, but had a significant effect on I Ca in mdx myocytes. Baseline I Ca was not changed in 2-and 3-month-old mdx myocytes compared with age-matched control myocytes, but was significantly increased in 4-and 12-month-old mdx myocytes compared with 2-and 3-month-old mdx and age-matched control myocytes ( Figure 6 and see Supplementary material online, Figure S4 ). When stimulated with ISO, maximum I Ca was increased to the same amplitude in 2-, 3-, and 4-month-old mdx and control myocytes. However, baseline I Ca in 12-month-old mdx myocytes was close to the I Ca after ISO in 12-month-old control myocytes and was not significantly increased by ISO ( Figure 6D and see Supplementary material online, Figure S4 ). These data suggest that, in mdx myocytes, I Ca is gradually enhanced, contributing to hypercontractile function of mdx myocytes older than 4 months.
Myocytes from
3.6 Increased ryanodine receptor expression and baseline phosphorylation of Cav1.2a1c, phospholamban, and ryanodine receptor 2 in 4-month-old mdx myocytes
To explore the molecular mechanisms of the enhanced basal contractile function but reduced beta-adrenergic response in 4-month-old mdx animal numbers used for studies (3 -15 cells were studied for each animal). A mixed-effects model was used to test differences at an overall P-value of 0.05 with Bonferroni adjustments. Post hoc tests were performed pairwise with Bonferroni adjustment. *P , 0.05, **P , 0.01, ***P , 0.001, respectively.
myocytes, the expression of Ca 2+ handling proteins and the phosphorylation state of phospholamban (PLB), ryanodine receptor 2 (RyR2), and Cav1.2a1c were determined. The abundance of PLB, sarco/endoplasmic reticulum Ca 2+ ATPase 2a (SERCA2a), Na + /Ca 2+ exchanger 1 (NCX1), Cav1.2a1c, Cav1.2b1, and Cav1.2b2 was not altered. In contrast, RyR2 was increased in 4-month-old mdx hearts compared with 4-month-old control hearts ( Figure 7A and B) . No change of Cav1.2a1c abundance was also supported by no difference in Cav1.2 charge movement between 4-month-old mdx and control myocytes (see Supplementary material online, Figure S5 ). The phosphorylation of Cav1.2a1c at Ser1928, RyR2 at the PKA site (Ser2809), PLB at the PKA site (Ser16), and the Ca 2+ /calmodulin-dependent kinase II (CaMKII) site (Thr17) was increased at baseline in 4-month-old mdx hearts compared with 4-month-old control hearts, but was not different between groups after ISO (10 27 M) ( Figure 7) . These results suggest that the activities of Cav1.2, SERCA2, and RyR2 could be enhanced at baseline in 4-month-old mdx hearts. 13 
Increased basal PKA activity, but reduced b1-AR in mdx myocytes
The increases in the phosphorylation of Ca 2+ handling proteins indicate that there could be an increase in basal PKA activity in 4-month-old mdx myocytes, which was confirmed by basal PKA activity measurement.
After ISO, PKA activity was similar between these two groups of hearts ( Figure 8A ). We found that the abundance of beta1-AR but not beta2-AR was reduced in mdx, compared with control hearts ( Figure 8B and C ). We further determined the impact of reduced beta1-AR density on myocyte sensitivity to ISO stimulation by measuring myocyte FS at baseline and after the application of 1, 5, 10, and 100 nM ISO. To avoid desensitization after the application of ISO, all cells were only exposed to one dose of ISO. As shown in Figure 8D , the FS of 4-month-old mdx myocyte was significantly reduced in response to 5 and 10 nM ISO compared with 4-month-old control myocytes, indicating a reduced sensitivity of mdx myocytes to betaadrenergic stimulation.
Discussion
It is still unknown if and how cardiac beta-adrenergic response, an indicator of early functional change of diseased hearts, is altered in young mdx hearts. In this study, we found that: (i) cardiac beta-adrenergic response of the heart in ≥4-month-old mdx mice was reduced in vivo and ex vivo compared with that in age-matched control and 2-month-old mdx hearts.
(ii) The myocytes isolated from ≥4-month-old mdx hearts had enhanced basal contractile function, but a further increase by ISO (4-month-old mdx myocytes) was reduced though contraction still Reduced cardiac beta-adrenergic response in mdx mice Figure 7 The expression and phosphorylation of calcium handling proteins in 4-month-old control and mdx hearts. (A and B) Western blot analysis of SERCA2a, PLB, NCX1, RyR2, Cav1.2a1c, Cav1.2b1, and Cav1.2b2 in 4-month-old mdx hearts was compared with that 4-month-old control hearts. (C-F) Western analysis of Cav1.2a1c phosphorylated at Ser1928 (C), RyR2 phosphorylated at Ser2815 and Ser2809 (D), PLB phosphorylated at Ser16 and Thr17 at baseline, and after ISO stimulation (E). The averaged phosphorylation level of these proteins is shown in (F ). Student's t-test was done for each protein in (B) and two-way ANOVAs for phosphorylated proteins in (F ).
attained similar maximal levels to those in the controls. However, this maximum was reduced in 8-and 12-month-old mdx myocytes. (iii) SR Ca 2+ content was not changed in 2-month-old mdx myocytes, was increased in 4-month-old mdx myocytes, and was decreased in 8-and 12-month-old mdx myocytes at baseline; ISO had reduced effects on the SR Ca 2+ content in mdx myocytes at ≥4 months old. (iv) Though the baseline I Ca did not change in control myocytes with age, it was increased in ≥4-month-old mdx myocytes. ISO enhanced I Ca to the same amplitude as in age-matched control myocytes. (v) The abundance of Cav1.2a1c, Cav1.2b1, Cav1.2b2, PLB, NCX, and SERCA was not altered, while RyR abundance was increased in 4-month-old mdx hearts. (vi) Basal phosphorylation of Cav1.2a1c, RyR2, and PLB was increased in 4-month-old mdx hearts but, after ISO, the phosphorylation of these proteins was comparable in mdx and control hearts. (vii) Basal PKA activity was increased, but beta1-AR abundance was decreased in 4-month-old mdx mice at baseline; 4-month-old mdx myocytes had reduced sensitivity to ISO stimulation.
Potential mechanisms for the reduced beta-adrenergic response
We found that cardiac beta-adrenergic responses of mdx hearts at ≥4 months old were reduced compared with those of either age-matched control hearts or mdx hearts at 2 months, which is before the alterations in global baseline cardiac function. The reductions of beta-adrenergic responses of mdx hearts are probably due to the following reasons. (i) The loss of myocytes: in agreement with previous studies, our study also showed substantial loss of myocytes revealed by significant replacement fibrosis in ≥4-month-old mdx hearts. In 4-and 8-month-old mdx hearts, at baseline no cardiac dysfunction was observed, probably due to a full compensation of myocyte loss by enhancing myocyte contraction. However, since the maximum ISO effect increased myocyte contraction in 4-and 8-month-old mdx mice to the same extent as in control myocytes, mdx hearts with fewer myocytes had poorer function compared with control hearts after ISO. In 8-and 12-month-old mdx hearts, the myocytes had reduced response to beta-adrenergic stimulation, which further decreased mdx cardiac function after ISO.
(ii) Hypercontractile function of mdx myocytes due to 'hyper'phosphorylation of multiple Ca 2+ handing proteins reduces the potential for ISO to increase myocyte function further. This could be a result of chronic stimulation by the SAS and other neurohormone systems. (iii) Desensitization of the beta-adrenergic signalling in the myocytes: the SAS could be activated in response to substantial loss of myocytes in ≥4-month-old mdx mice, suggested by heightened basal heart rates in DMD patients and mdx mice.
14 . Increased basal PKA activity and phosphorylation of Ca 2+ handling proteins also suggest hyperactivity of the SAS in mdx mice (Figures 7 and 8) . Persistent activation of the SAS could lead to desensitization of the beta-adrenergic signalling in cardiomyocytes. 12 Our study shows that the expression of b1-AR is significantly reduced in 4-month-old mdx hearts, and mdx myocytes had reduced sensitivity to ISO. It has been reported that there is a reduction of beta1-AR density and sensitivity in 12-month-old mdx, but not in 3-month-old mdx, atria. 15 The slight difference in the timing of the b1-AR decrease could be due to differences in ages (4 vs. 3 months) and tissues (ventricles vs. atria). The fact that the heart rates of 2-, 4-, 8-, and 12-month-old mdx hearts respond almost normally to different doses of ISO implies that the sinoatrial nodal cells might maintain a normal density of b-ARs, arguing for differential regulation of b-AR density in different Reduced cardiac beta-adrenergic response in mdx mice parts of the mdx heart. The impairment of cardiac relaxation in ≥4-month-old mdx hearts after ISO and in mdx hearts older than 8 months at baseline could be related to both the alterations of myocyte function and the increases in myocardial fibrosis. Therefore, measurement of myocardial fibrosis with an advanced non-invasive technique could be a reliable and valuable prognostic marker for cardiac dysfunction.
Remodelling of calcium handling in young mdx myocytes
When a stressed heart is at its compensated stage, the myocytes may develop a hypercontractile function to overcome the stress and maintain cardiac output. 13, 16 In this study, young mdx myocytes were found to be hypercontractile. Enhanced myocyte contraction in young mdx myocytes may be due to increases in I Ca , PLB phosphorylation, and resultant SR Ca 2+ load. The increase in I Ca may only partially account for the increase of SR Ca 2+ load because there is increased Ca 2+ influx via other routes. 17 In addition, at baseline, enhanced phosphorylation of PLB could increase SERCA activity to allow more Ca 2+ uptake into the SR. Previously, Williams and Allen 16 found that the phosphorylation of PLB at the Ser16 site is decreased in both 2-to 3-month-old and 9-to 12-month-old mice. Another study by Sarma et al. 18 found no change in PLB phosphorylation at Ser16 in 3-and 15-month-old hearts. These differences could be related to the differences in ages of animals used and the experimental conditions. In our study, we also showed increased RyR phosphorylation at both PKA and CaMKII sites that may cause Ca 2+ to leak out of the SR. However, we observed a higher basal SR 20 and oxidation. 21 The phosphorylation levels of Cav1.2a1c, RyR, and PLB are increased in 4-month-old mdx hearts. Previously, it was found that there is increased phosphorylation of RyR at both PKA and CaMKII sites in 12-month-old mdx, but not in 3-month-old mdx, hearts. 18 Currently, it is not known how these proteins become highly phosphorylated in mdx hearts. Both a high basal PKA and CaMKII activity and a low phosphatase activity could result in 'hyper'phosphorylation of some molecules, as observed in isolated failing human myocytes. 22, 23 Our study
shows that the baseline PKA activity is greater in isolated mdx hearts and myocytes. We have previously reported similar observations in mouse myocytes deficient in G-protein receptor kinase 2 24 and failing human VMs. 25 The molecular mechanisms responsible for this increase in basal PKA activity remain to be determined and could be related to an enhanced basal activity of the b-AR/Gs/adenylyl cyclase signalling and/or a decrease in phosphodiesterase activity. These molecular alterations could account for the enhanced myocyte contraction.
Increased I Ca in young mdx cardiomyocytes
We have shown that I Ca density is increased in VMs of ≥4-month-old mdx mice. Significant increases in Cav1.2 density (measured by ligand binding), and Cav1.2a1c protein and mRNA abundance in 3-month-old mdx hearts, were reported previously. 26 Previous studies of I Ca in neonatal, 27 ,28 1-month-old, 21 and 2-month-old 29 mdx mice showed no change of I Ca density, as our study indicates that I Ca change could only appear after the age of 4 months; Ullrich et al. 30 showed a non-significant change of I Ca (wild type, 25.36 + 0.09, n ¼ 20 vs. mdx 25.81 + 0.37, n ¼ 16; P ¼ 0.20, two-tailed Student's t-test) in 6-to 12-month-old mdx mice. These data, together with our data (Figure 6 ), suggest a dynamic alteration and gradual increase of I Ca during the progression of the disease. In our study, we did not detect changes in Cav1.2a1c expression by either western blot or charge movement measurement, but rather a significant increase in I Ca density was found in VMs from 4-month-old mdx mice, indicating a significant increase in Cav1.2 activity in young mdx hearts. The increased phosphorylation of Cav1.2a1c could account for the increased Cav1.2 activity. In addition, the lack of an effect of dystrophin in decreasing the rate of I Ca inactivation 28 might also contribute to enhanced Cav1.2 activity in 4-month-old mdx myocytes.
Significance of our study
During the past decade, better support for respiratory function makes cardiomyopathy and arrhythmias important contributing factors to the mortality of DMD patients. 31 Our study showed that, in young mdx mice, reduced cardiac beta-adrenergic responses are an indication of early cardiac dysfunction. It remains to be determined whether this also occurs in young DMD patients because of differences in the progression of cardiomyopathy in human DMD patients and mdx mice. 8 Though it is possible to perform exercise or dobutamine tests in very young DMD patients who are still capable of exercise, such tests in DMD patients become difficult at later stages. 8 Our study suggests that chronic activation of the SAS in mdx/DMD may promote the progression of cardiomyopathy, and treatments with beta-blockers or beta-blockers in combination with other drugs such as angiotensinconverting enzyme inhibitors for cardiac complications in DMD patients might be considered at a younger age. Future approaches could include blocking hyperactive PKA 18 and CaMKII. 32 Our study also suggests that the interplay between substantial cardiomyocyte loss and the activation of SAS to maintain cardiac function promotes cardiomyopathy. It seems that hyperactivity of the SAS and the hypercontractile function of cardiac myocytes compensate for substantial loss of cardiomyocytes in mdx hearts. However, these alterations promote myocyte death, forming a vicious cycle promoting cardiac failure in mdx mice and DMD patients.
Conclusion
Mdx hearts partially lose beta-adrenergic responses from a young age (4 months) because of myocyte loss, reduced potential for increasing myocyte contraction in mdx myocytes with enhanced myocyte contractile function via molecular remodelling, and cellular desensitization in response to the hyperactive SAS. Although cellular remodelling exerts some beneficial effects in mdx hearts, in the long run it may contribute to the progression of cardiomyopathy in mdx hearts.
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